Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | SI | P14410 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomatin SCHEMBL6273711 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL31349688 | 0.82 | KDM4E (0.81) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL29707867 | 0.79 | KDM4E (0.76) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL15444379 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Jatamansin SCHEMBL30634819 | 0.77 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Jatamansin SCHEMBL29385603 | 0.77 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Jatamansin SCHEMBL14523891 | 0.77 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Jatamansin SCHEMBL12062120 | 0.77 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL29624043 | 0.75 | L3MBTL1 (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL4743847 | 0.75 | L3MBTL1 (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112941000-B | Escherichia coli strain and method for biologically synthesizing pyranocoumarin and furocoumarin by using same | 上海交通大学 | 2022-10-21 | — | — | CN | claimed |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| CN-117187268-A | CYP450 cyclase gene PpDC and PpOC for synthesizing complex coumarin and application thereof | 中国药科大学 | 2023-12-08 | — | — | CN | disclosed |
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | disclosed |
| CN-112941000-B | Escherichia coli strain and method for biologically synthesizing pyranocoumarin and furocoumarin by using same | 上海交通大学 | 2022-10-21 | — | — | CN | disclosed |
| EP-4022058-A2 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | KDM4E 3992/4885ALDH1A1 2270/4885HPGD 4360/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | KDM4E 3992/4885ALDH1A1 2270/4885HPGD 4360/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | KDM4E 3992/4885ALDH1A1 2270/4885HPGD 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.